We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research. Vision loss affects 253 million people worldwide, presenting a major global health problem and diseases of the retina are among the main causes of visual impairment globally.

We have the broadest late stage retina pipeline including treatments for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Our robust early stage pipeline also includes novel therapeutic modalities such as gene therapies, cell-based therapies and potential treatments for geographic atrophy (GA).

Our experienced team of ophthalmologists, scientists and researchers are working to develop innovative solutions that have the potential to preserve and restore vision.

Partnering opportunities we are looking for:

  • Retinal diseases and long-acting ocular drug delivery solutions

  • Glaucoma and dry eye disease

Example partnerships

Forsight Vision4Lineage Cell TherapeuticsSemaThera

Your dedicated partnering leads in Ophthalmology

Interested in partnering with us?

If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.

More Pharma partnering areas

View all areas


  1. Word Health Organization. Blindness and vision impairment. [Internet; cited April 2022]. Available from:

Discover more

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeCovid-19Pharma solutionsRoche careersMedia libraryAnnual Report 2023Privacy policyLegal statement